Search results
Results From The WOW.Com Content Network
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2]
Xanomeline was licensed to Karuna Therapeutics in 2012 and KarXT was subsequently created as a dual drug formulation by adding trospium. Trospium is a non-brain-penetrant and non-selective muscarinic receptor blocker that may ameliorate the peripheral side effects of xanomeline.
Karyopharm Therapeutics (NASDAQ: KPTI) Q4 2024 Earnings Call Feb 19, 2025, 8:00 a.m. ET. Contents: ... we should be able to launch rapidly because we have already trusted relationships with many ...
Repros Therapeutics Inc. was a US-based development stage biopharmaceutical company headquartered in The Woodlands, Texas. Founded in 1987 as Zonagen, it focused on the development of oral small molecule drugs to address major unmet medical needs in male and female health. Joseph S. Podolski was the CEO of this company. [1]
Illustrating this trend, in March 2024, Tonix Pharmaceuticals Holding Corp. collaborated with EVERSANA®, a prominent global commercialization services provider, to support the launch strategy and commercial planning for Tonmya™ (TNX-102 SL), a fibromyalgia drug in development for the U.S. market.
LONDON AND PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announces that it has sold Launch Diagnostics Holdings Limited (“Launch Diagnostics”) and its subsidiaries, its UK-based and largest ...
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. [6] Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna . As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing .
Update on NCX 470 Development In addition to the Denali clinical trial, other development activities to support the preparation of a New Drug Application in the U.S. and China, where NCX 470 is partnered with Ocumension Therapeutics, are ongoing. These include supporting clinical and non-clinical trials and pharmaceutical development.